These results were presented simultaneously at the AACR Annual Meeting 2022 in New Orleans, Louisiana, USA. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group AACR Annual Meeting 2022; New Orleans, Louisiana, USA: 8–13 April N Engl J Med 2022; doi:10.1056/NEJMoa2202170 N Engl J Med 2022; doi:10.1056/NEJMe2203330

Adding nivolumab to neoadjuvant chemotherapy significantly improves the pathologic complete response rate in patients with resectable non-small-cell lung cancer, shows the CheckMate 816 trial reported at the virtual AACR Annual Meeting 2021.

Adding nivolumab to neoadjuvant chemotherapy for resectable non-small-cell lung cancer is not associated with surgical delays or complications, show CheckMate 816 data presented at the 2021 ASCO Annual Meeting.

However, a higher proportion of sintilimab- than docetaxel-treated patients discontinued due to TRAEs (12.5 vs 5.4%), and the rate of death attributable to TRAEs was also higher (3.5 vs 0.8%). medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group AACR Annual Meeting 2021; 10–15 April

“Novel combinatorial strategies will be necessary to delay or overcome resistance in KRAS G12C-mutant cancers,” concluded Awad. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group AACR Annual Meeting 2021; 10–15 April

Zhou concluded that tislelizumab “produced meaningful clinical benefit” over docetaxel when given as second-or third-line monotherapy in NSCLC. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group AACR Annual Meeting 2021; 10–15 April

He added: “Future work is needed to validate this new parameter to verify its utility for clinical practice.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group AACR Annual Meeting 2021; 10–15 April

The findings, presented at the virtual AACR Annual Meeting 2021, were based on a next-generation sequencing analysis of tumors from 299 patients with NSCLC who had been treated with ICIs.

Data from the NEPTUNES trial were presented by Mark Linch, from the University College London Cancer Institute in the UK, at the virtual AACR Annual Meeting 2021.

The study data were presented in a poster by Anna Plym (Brigham and Women's Hospital, Boston, Massachusetts, USA) and colleagues at the virtual AACR Annual Meeting 2021.